Wanbury Share Price
Start SIP in Wanbury
Start SIPWanbury Performance
Day Range
- Low 241
- High 254
52 Week Range
- Low 82
- High 290
- Open Price252
- Previous Close247
- Volume43130
Wanbury Investment Rating
-
Master Rating:
-
Wanbury has an operating revenue of Rs. 560.47 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 10% is healthy, ROE of 200% is exceptional. The company has a high debt to equity of 293%, which can be a reason to worry. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 45% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 131 | 139 | 145 | 144 | 146 | 133 |
Operating Expenses Qtr Cr | 120 | 121 | 124 | 127 | 133 | 119 |
Operating Profit Qtr Cr | 11 | 18 | 21 | 17 | 13 | 14 |
Depreciation Qtr Cr | 3 | 3 | 3 | 3 | 3 | 3 |
Interest Qtr Cr | 8 | 7 | 8 | 8 | 6 | 8 |
Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Net Profit Qtr Cr | 1 | 8 | 10 | 7 | 5 | 1 |
Wanbury Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 7
- Bearish Moving Average
- ___
- 9
- 20 Day
- ₹253.12
- 50 Day
- ₹237.20
- 100 Day
- ₹212.56
- 200 Day
- ₹179.65
- 20 Day
- ₹260.80
- 50 Day
- ₹235.38
- 100 Day
- ₹202.14
- 200 Day
- ₹175.17
Wanbury Resistance and Support
Resistance | |
---|---|
First Resistance | 254.80 |
Second Resistance | 260.90 |
Third Resistance | 267.80 |
RSI | 48.90 |
MFI | 24.85 |
MACD Single Line | 6.47 |
MACD | 2.79 |
Support | |
---|---|
First Support | 241.80 |
Second Support | 234.90 |
Third Supoort | 228.80 |
Wanbury Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 51,823 | 5,182,300 | 100 |
Week | 61,019 | 6,101,880 | 100 |
1 Month | 120,194 | 12,019,355 | 100 |
6 Month | 187,790 | 13,665,455 | 72.77 |
Wanbury Result Highlights
Wanbury Synopsis
NSE-Medical-Generic Drugs
Wanbury is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 575.65 Cr. and Equity Capital is Rs. 32.75 Cr. for the Year ended 31/03/2024. Wanbury Ltd. is a Public Limited Listed company incorporated on 11/08/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L51900MH1988PLC048455 and registration number is 048455.Market Cap | 809 |
Sales | 560 |
Shares in Float | 1.96 |
No of funds | 6 |
Yield |
Book Value | 28.96 |
U/D Vol ratio | 1.2 |
LTDebt / Equity | 293 |
Alpha | 0.35 |
Beta | 1.06 |
Wanbury Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Dec-23 |
---|---|---|---|
Promoters | 39.79% | 39.79% | 39.79% |
Mutual Funds | |||
Foreign Portfolio Investors | 0.22% | 0.18% | |
Financial Institutions/ Banks | |||
Individual Investors | 41.41% | 41.81% | 39.09% |
Others | 18.58% | 18.22% | 21.12% |
Wanbury Management
Name | Designation |
---|---|
Mr. K Chandran | Vice Chairman & Whole Time Dir |
Ms. Anupama Vaidya | Ind. Non-Executive Woman Director |
Mr. Mohan Kumar Rayana | Whole Time Director |
Mr. Pravin Dilip Pawar | Ind. Non-Executive Director |
Mr. Mridul Sumanlal Mehta | Addnl.Non Exe.Independent Director |
Wanbury Forecast
Price Estimates
Wanbury Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-12 | Quarterly Results | |
2024-05-16 | Audited Results | |
2024-01-24 | Quarterly Results | |
2023-10-20 | Quarterly Results & Preferential issue | Inter-alia, to consider and evaluate proposals for raising of funds by way of a preferential issue/allotment and private placement to promoters/promoter group of the Company. |
2023-08-11 | Quarterly Results |
Wanbury FAQs
What is Share Price of Wanbury ?
Wanbury share price is ₹248 As on 15 October, 2024 | 19:11
What is the Market Cap of Wanbury ?
The Market Cap of Wanbury is ₹814.4 Cr As on 15 October, 2024 | 19:11
What is the P/E ratio of Wanbury ?
The P/E ratio of Wanbury is 15.6 As on 15 October, 2024 | 19:11
What is the PB ratio of Wanbury ?
The PB ratio of Wanbury is 29.1 As on 15 October, 2024 | 19:11
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.